Dawid Lyszczek is an expert new product developer, food technologist, nutritionist and personal trainer. He holds a bachelor’s degree in Human Nutrition, master’s degree in Food Innovation and Level 3 Certificate in Personal Training. Dawid specialises in evidence-based body-composition nutrition and training for both amateurs and physique athletes, and has been involved in sports nutrition and weight training for over 15 years. Dawid is also a former competitive bodybuilder, UKBFF British finalist in “Intermediates Over 90kgs” Class of 2013, as featured in Flex magazine.
Dawid’s academic area of interest has involved both the role of meal frequency on body composition, and also functional food development, which you can find out more about here.
In his current role, Dawid bridges the gap between sports nutrition and food technology, bringing in academic experience backed by real life practice that produces results.
You can find out more about Dawid’s experience here.
1. Young SN (2007). “How to increase serotonin in the human brain without drugs”. Rev. Psychiatr. Neurosci. 32 (6): 394–99. http://www.sciencedirect.com/science/article/pii/S030105111200230X
2. Birdsall, T. C. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 3, 271–280. http://www.altmedrev.com/publications/3/4/271.pdf
3. Magnussen IE, Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in a steady state. Acta Pharmacol Toxicol 1980;46:257-262. http://www.ncbi.nlm.nih.gov/pubmed/6966118
4. Magnussen I, Jensen TS, Rand JH, Van Woert MH. Plasma accumulation of metabolism of orally administered single dose L-5- hydroxytryptophan in man. Acta Pharmacol Toxicol 1981;49:184-189. http://www.ncbi.nlm.nih.gov/pubmed/6175178
5. Turner, E.H., Loftis, J.M. and Blackwell, A.D., 2006. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & therapeutics, 109(3), pp.325-338. http://www.anth.ucsb.edu/faculty/blackwell/Documents/5-HTP.Pharm.Therap.pdf
6. Ceci, F., Cangiano, C., Cairella, M., Cascino, A., Del Ben, M., Muscaritoli, M., Sibilia, L. and Fanelli, F.R., 1989. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. Journal of neural transmission, 76(2), pp.109-117. http://www.ncbi.nlm.nih.gov/pubmed/2468734
7. Cangiano, C., Ceci, F., Cascino, A., Del Ben, M., Laviano, A., Muscaritoli, M., Antonucci, F. and Rossi-Fanelli, F., 1992. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. The American journal of clinical nutrition, 56(5), pp.863-867. http://www.ncbi.nlm.nih.gov/pubmed/1384305
8. Ju CY, Tsai CT. Serotonergic mechanisms involved in the suppression of feeding by 5-HTP in rats. Chin J Physiol 1995;38:235–40. http://www.ncbi.nlm.nih.gov/pubmed/8925676
9. Cangiano C, Laviano A, Del Ben M, Preziosa F, Angelico F, Cascino A, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and mac- ronutrient selection in non-insulin dependent diabetic patients. Int J Obes Relat Metab Dis 1998;22:648–54. http://www.ncbi.nlm.nih.gov/pubmed/9705024
10. Amer, A., Breu, J., McDermott, J., Wurtman, R.J. and Maher, T.J., 2004. 5-Hydroxy-L-tryptophan suppresses food intake in food-deprived and stressed rats. Pharmacology Biochemistry and Behavior, 77(1), pp.137-143. http://www.ncbi.nlm.nih.gov/pubmed/14724051
11. Halford JC, Blundell JE. Pharmacology of appetite suppression. Prog Drug Res 2000;54:25–58. http://www.ncbi.nlm.nih.gov/pubmed/10857385
12. Portas, C.M., Bjorvatn, B. and Ursin, R., 2000. Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Progress in neurobiology, 60(1), pp.13-35. http://www.ncbi.nlm.nih.gov/pubmed/10622375
13. Wyatt, R.J., Engelman, K., Kupfer, D.J., Scott, J., Sjoerdsma, A. and Snyder, F., 1969. Effects of para-chlorophenylalanine on sleep in man. Electroencephalography and clinical neurophysiology, 27(5), pp.529-532. http://www.ncbi.nlm.nih.gov/pubmed/4187039
14. Wyatt, R. J. Serotonin and sleep. In A. SJOERDSMA (Ed.), Serotonin now: clinical implications of inhibiting its” syntheses with parachlorophenylalanine. Ann. intern. Med., 1970, 73:607 629. http://www.ncbi.nlm.nih.gov/pubmed/4319081
15. Wyatt, R.J., Zarcone, V., Engelman, K., Dement, W.C., Snyder, F. and Sjoerdsma, A., 1971. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalography and clinical neurophysiology, 30(6), pp.505-509. http://www.ncbi.nlm.nih.gov/pubmed/4105646
16. Ellman, S.J., Spielman, A.J., Luck, D., Steiner, S.S. and Halperin, R., 1978. REM deprivation: a review. In The mind in sleep (pp. 419-457). Erlbaum Hillsdale, NJ.
17. Horne, J., 2013. Why REM sleep? Clues beyond the laboratory in a more challenging world. Biological psychology, 92(2), pp.152-168. http://www.ncbi.nlm.nih.gov/pubmed/23174692
18. Monti, J.M., 2011. Serotonin control of sleep-wake behavior. Sleep medicine reviews, 15(4), pp.269-281. http://www.ncbi.nlm.nih.gov/pubmed/21459634
19. Shell, W., Bullias, D., Charuvastra, E., May, L.A. and Silver, D.S., 2010. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. American journal of therapeutics, 17(2), pp.133-1. http://ptloffice.com/downloads/marketing/GABAdone20paper20May202009.pdf
20. Meyers S. Use of neurotransmitter precursors for treatment of depression. Altern Med Rev. 2000;5(1):64–71. http://www.ncbi.nlm.nih.gov/pubmed/10696120
21. Tomas-Carus, P., Branco, J.C., Raimundo, A., Garcia, J., Sousa, P.M. and Biehl-Printes, C., 2015. [Relationships between widespread pain and thresholds pain tolerance on tender points in Portuguese women with fibromyalgia: impact on daily life.]. Acta reumatologica portuguesa. 40, 3, 254-61. http://www.ncbi.nlm.nih.gov/pubmed/25941898
22. On, A.Y., 2016. Fibromyalgia or chronic widespread pain: Does it matter?. Itch & Pain, 3. http://www.google.com/url?url=http://www.smartscitech.com/index.php/IP/article/download/1079/pdf_12&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwj0ue7XhsrKAhWFpw4KHcQ4BOEQFggZMAE&usg=AFQjCNEhqB5H86B8WifBEB6qB5mfhI96VQ
23. Mosely L. (2014) Everything you wanted to know about CENTRAL SENSITISATION. Body in Mind. http://www.bodyinmind.org/central-sensitisation/
24. Caruso, I., Puttini, P.S., Cazzola, M. and Azzolini, V., 1990. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. Journal of International Medical Research, 18(3), pp.201-209. http://imr.sagepub.com/content/18/3/201.full.pdf
25. Puttini, P.S. and Caruso, I., 1992. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. Journal of international medical research, 20(2), pp.182-189. http://www.ncbi.nlm.nih.gov/pubmed/1521674
26. Neogi, T., 2016. Joint Pain Epidemiology. http://iasp.files.cms-plus.com/Content/ContentFolders/GlobalYearAgainstPain2/2016/FactSheets/English/11.%20Joint%20Pain%20Epidemiology.pdf
27. Yang, T.H., Hsu, P.Y., Meng, M. and Su, C.C., 2015. Supplement of 5-hydroxytryptophan before induction suppresses inflammation and collagen-induced arthritis. Arthritis research & therapy, 17(1), pp.1-12. http://www.arthritis-research.com/content/pdf/s13075-015-0884-y.pdf
28. Hinz M, Stein A, Uncini T. The discrediting the monoamine hypothesis: a case study. Int J Gen Med. 2012;5:135–142. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282597/
29. Hinz M, Stein A, Uncini T. Relative nutritional deficiencies associated with centrally acting monoamines. Int J Gen Med. 2012;5:413–430. http://www.ncbi.nlm.nih.gov/pubmed/22615537
30. Das, Y.T., Bagchi, M., Bagchi, D. and Preuss, H.G., 2004. Safety of 5-hydroxy-L-tryptophan. Toxicology letters, 150(1), pp.111-122. http://www.ncbi.nlm.nih.gov/pubmed/15068828
31. Hinz M, Stein A, Uncini T. APRESS: apical regulatory super system, serotonin, and dopamine interaction. Neuropsychiatr Dis Treat. 2011;7:457–463. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157489/
